Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas.
Gastroenterology. 2019 May;156(7):2024-2040. doi: 10.1053/j.gastro.2019.01.259. Epub 2019 Feb 2.
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic, surgically unresectable disease. Although the goal of early detection of PDAC is laudable and likely to result in significant improvement in overall survival, the relatively low prevalence of PDAC renders general population screening infeasible. The challenges of early detection include identification of at-risk individuals in the general population who would benefit from longitudinal surveillance programs and appropriate biomarker and imaging-based modalities used for PDAC surveillance in such cohorts. In recent years, various subgroups at higher-than-average risk for PDAC have been identified, including those with familial risk due to germline mutations, a history of pancreatitis, patients with mucinous pancreatic cysts, and elderly patients with new-onset diabetes. The last 2 categories are discussed at length in terms of the opportunities and challenges they present for PDAC early detection. We also discuss current and emerging imaging modalities that are critical to identifying early, potentially curable PDAC in high-risk cohorts on surveillance.
大多数胰腺导管腺癌(PDAC)患者表现为有症状且无法手术切除的疾病。尽管早期检测 PDAC 的目标值得称赞,并且可能会显著改善总体生存率,但 PDAC 的相对低患病率使得一般人群筛查变得不可行。早期检测的挑战包括识别一般人群中处于高危状态的个体,这些个体将从纵向监测计划中受益,以及在这些队列中用于 PDAC 监测的适当生物标志物和基于成像的模式。近年来,已经确定了各种高于平均水平患 PDAC 风险的亚组,包括由于种系突变导致的家族性风险、胰腺炎病史、粘液性胰腺囊肿患者以及新诊断糖尿病的老年患者。后两个类别详细讨论了它们为 PDAC 早期检测带来的机遇和挑战。我们还讨论了当前和新兴的成像方式,这些方式对于在监测中识别高危人群中早期、潜在可治愈的 PDAC 至关重要。